StackwiseStackwise
medication

Tranylcypromine

Also known as: Parnate, MAOI

Chemical structure of Tranylcypromine (PubChem CID 5530)
Structure via PubChem
Half-life
2.5 h
Typical timing
morning
Food rule
either
Default unit
mg

Overview

Tranylcypromine, often known by its brand name Parnate, is a medication classified as a non-selective, irreversible monoamine oxidase inhibitor (MAOI). It is primarily used to treat major depressive disorder, particularly in individuals who have not responded adequately to other antidepressant therapies (NIH MedlinePlus). As an MAOI, it works by inhibiting the activity of monoamine oxidase enzymes in the body, which are responsible for breaking down neurotransmitters such as serotonin, norepinephrine, and dopamine. The resulting increase in the levels of these neurotransmitters in the brain is thought to contribute to its antidepressant effects. Tranylcypromine has a relatively short half-life of approximately 2.5 hours, but its pharmacological effects persist much longer due to its irreversible inhibition of MAO enzymes (DrugBank).

Deep dive

Tap a section to expand.

Known interactions

  • Category rule: supplement × medication
    Note

    Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).

    Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist.

  • Category rule: vitamin × medication
    Note

    Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).

    Specific pairs are checked against a licensed source; confirm with your provider.

  • Compound-pair rule
    Avoid

    Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.

    Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).

  • Compound-pair rule
    Avoid

    Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.

    Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).

  • Compound-pair rule
    Avoid

    Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.

    Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).

  • Compound-pair rule
    Avoid

    Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.

    Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).

  • Compound-pair rule
    Avoid

    Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.

    Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).

  • Compound-pair rule
    Avoid

    Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.

    Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).

  • Compound-pair rule
    Avoid

    Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.

    Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).

  • Compound-pair rule
    Avoid

    Combining SSRIs/SNRIs with MAOIs can cause life-threatening serotonin syndrome.

    Do not combine. Allow at least 14 days between stopping one and starting the other (5 weeks for fluoxetine).

  • Compound-pair rule
    Avoid

    MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.

    Do not combine.

  • Compound-pair rule
    Avoid

    MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.

    Do not combine.

  • Compound-pair rule
    Avoid

    MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.

    Do not combine.

  • Compound-pair rule
    Avoid

    MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.

    Do not combine.

  • Compound-pair rule
    Avoid

    MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.

    Do not combine.

  • Compound-pair rule
    Avoid

    MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.

    Do not combine.

  • Compound-pair rule
    Avoid

    MAOI blocks catecholamine breakdown; combining with sympathomimetics can trigger hypertensive crisis.

    Do not combine.

Sources referenced

- Cochrane Library - DrugBank - Examine.com - FDA (U.S. Food and Drug Administration) label - Mayo Clinic - NIH MedlinePlus - NIH National Institute of Mental Health - PubChem

Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.

Related compounds

Others in the medication category or studied for the same goals.

Track Tranylcypromine in Stackwise

Add it to your stack. We'll schedule doses, check interactions against everything else you take, and remind you at the right time.

Sign up free →